{"Clinical Trial ID": "NCT00331630", "Intervention": ["INTERVENTION 1:", "Treatment with Lapatinib and Abraxane", "30 patients receive Abraxane IV more than 30 minutes on day 1 and oral lapatinib once daily on days 1 to 21. Treatment is repeated every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.", "Lapatinib Ditosylate: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment is repeated every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.", "\u2022 Formulation of stabilized nanoparticles by paclitaxel albumin: 30 patients receive Abraxane IV for 30 minutes on day 1 of each treatment cycle. Treatment is repeated every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "- Breast cancer confirmed histologically", "Clinical stage I-III disease", "A measurable disease defined as a one-dimensional injury measuring 20 mm by conventional techniques OR 10 mm with spiral scan", "HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization", "No known brain metastases", "Unspecified hormonal receptor status", "CHARACTERISTICS OF PATIENTS:", "\u2022 Menopausal status not specified", "Men or women", "Life expectancy > 12 weeks", "\u2022 ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%", "WBC 3.000/mm^3", "Absolute number of neutrophils 1,500 mm^3", "Number of platelets 100 000/mm^3", "Total normal bilirubin", "ASAT and ALT 2.5 times the upper limit of normal", "OR creatinine clearance 60 mL/min", "LVEF 50% measured by echocardiogram or MUGA analysis", "No other malignity in the past year", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception", "\u2022 Capable of swallowing and conserving oral medicines", "No history of allergic reactions attributed to compounds of chemical or biological composition similar to lapatinib", "No infection in progress or active", "No symptomatic congestive heart failure", "No unstable breast angina", "No cardiac arrhythmia", "No psychiatric illness or social situation that would prevent compliance with the study", "No other uncontrolled diseases", "No gastrointestinal disease (GI) that would prevent oral medication", "No malabsorption syndrome", "No requirement for feeding IV", "No uncontrolled IG inflammatory disease (e.g. Crohn's disease or ulcerative colitis)", "THERAPE PRIOR CONCURENT:", "No chemotherapy, immunotherapy, radiotherapy or prior hormonal treatment for breast cancer", "No previous treatment with epidermal growth factor receptor targeting therapies", "No previous surgery affecting absorption", "No previous breast cancer surgery", "At least 14 days after the use of previous and non-concomitant CYP3A4 inducers, including any of the following:", "Dexamethasone or equivalent dose to dexamethasone 1.5 mg/day, including one of the following doses:", "- Cortisone ( 50 mg/day)", "- Hydrocortisone ( 40 mg/day)", "Prednisone ( 10 mg/day)", "Methylprednisolone ( 8 mg/day)", "Phenytoin", "- Carbamazepine", "Phenobarbital", "Efavirenz", "Nevirapine", "- Rifampin", "- Rifabutin", "- Rifapentin", "Hypericum perforatum (St John's wort)", "- Modafinil", "At least 7 days after previous CYP3A4 inhibitors and no concomitant CYP3A4 inhibitors, including any of the following:", "- Clarithromycin", "Erythromycin", "Troleandomycin", "- Delavirdine", "- Ritonavir", "Indinavir", "- Saquinavir", "- Nelfinavir", "Amprenavir", "- Lopinavir", "Itraconazole", "- Ketoconazole", "Voriconazole", "Fluconazole (doses up to 150 mg/day are allowed)", "Nefazodone", "- Fluvoxamine", "- Verapamil", "- Diltiazem", "Cimetidine", "Aprepitant", "\u2014 Grapefruit or their juices", "At least 6 months since the previous one and no simultaneous amiodarone", "At least 2 days from the beginning and no simultaneous gastric modifier of pH*, including any of the following:", "Cimetidine", "- Ranitidine", "Nizatidine", "- Famotidine", "Omeprazole", "Esomeprazole", "Rabeprazole", "- Pantoprazole", "- Lansoprazole", "NOTE: *Antacids are allowed within 1 hour before and after administration of the study drug", "No other competing search agent", "No other concomitant anticancer therapy including chemotherapy, radiotherapy, immunotherapy or hormonal antitumour therapy", "No concomitant herbal medicines (alternative)", "No combination antiretroviral therapy concomitantly for HIV-positive patients", "Allowed concurrent biphosphonates"], "Results": ["Performance measures:", "Clinical response rate (CRc)", "RRC measured by RECIST for target lesions assessed by ultrasound (US) mammography+ clinical examination. RRC is defined as the number of patients who have the best response in one of the evaluations (clinical examination/mammography/US) is CR+PR. The response will be defined as one of the following in the clinical examination, mammography or US: Complete response (CR)-Disappearance of all target lesions. Partial response (PR)>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the base sum.", "A stable disease - neither a shrinkage sufficient to qualify for a partial disease, nor an increase sufficient to qualify for a progressive disease, taking as a reference the smallest sum of LD during the study.", "The progressive disease <=20% increases the sum of the LD of the target lesions, taking as a reference the smallest sum of LD recorded since the start of treatment or the occurrence of one or more new lesions.", "At the baseline stage, then before the start of each treatment cycle and after 4 treatment cycles under study (1 cycle = 21 days)", "Results 1:", "Title of the arm/group: Treatment with lapatinib and abraxane", "30 patients receive Abraxane IV for 30 minutes on day 1 and oral lapatinib once daily on days 1 to 21. Treatment is repeated every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.", "Lapatinib Ditosylate: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment is repeated every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.", "\u2022 Formulation of stabilized nanoparticles by paclitaxel albumin: 30 patients receive Abraxane IV for 30 minutes on day 1 of each treatment cycle. Treatment is repeated every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.", "Total number of participants analysed: 29", "Type of measurement: Number", "Unit of measure: Participants Complete response: 6", "Partial reply: 18", "Stable disease: 5", "Progressive diseases: 0", "Clinical response rate: 24"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/30 (6.67 per cent)", "- Dry eyes [1]1/30 (3.33%)", "Diarrhoea [2]1/30 (3.33%)"]}